Lundbeck has ended its bidding war with Alkermes to acquire Avadel Pharmaceuticals, saying that it will not increase its offer for the sleep disorder drug developer beyond the approximately $2.4 ...

Researchers say in future it may be possible to grow personalized organoids from patient’s own tissue, to test potential treatments in advance.

IBP-9414 will be the first live biotherapeutic product globally, according to officials at Infant Bacterial Therapeutics in Stockholm.

Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

Study shows social isolation following immune challenge is self-imposed and driven by an active neural process, rather than a secondary consequence of physiological symptoms of sickness.

This academic-industry partnership reflects the need for a multidisciplinary approach to innovation in cell and gene therapy manufacturing.

EVE is a deep generative model combining evolutionary and human population data to estimate variant deleteriousness on a proteome-wide scale.

Precipitation-based purification method could replace current Protein A–reliant methods, significantly reducing manufacturing costs of mAbs.

The U.S. is AstraZeneca’s largest market by sales and is also home to 19 R&D, manufacturing, and commercial sites.

Sustainable bioprocessing boosts cyanobacterial pigment production for advanced biomedical, imaging, and commercial applications.

The U.S. Pharmacopeia has created new standards to support the emerging field of advanced cell and gene therapies.

Multiple microbial communities populate cleanrooms, regardless of grade, and aren’t detected by standard monitoring methods.